Celator Pharma Revenue, Profits - CPXX Quarterly Income Statement

Add to My Stocks
$30.24 $0 (0%) CPXX stock closing price Jul 14, 2016 (Closing)

Financial analysis of Celator Pharma involves more than just checking the Celator Pharma stock price, by looking at the financial statements of the company in detail. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. The income statement for CPXX which shows a YOY revenue decline of 0 is specific to a period of time. Investors typically check YoY or QoQ revenue growth. The Celator Pharma profit and loss statement for 2016 Q1 shows a net profit of $-5.53M. Profits for last year was $-4.41M. Apart from this an investor should also check Celator Pharma assets and Celator Pharma free cash flow.

View and download details of revenue and profits for Celator Pharma for latest & last 40 quarters.
show more
Fiscal year is Jan - Dec2016 Q12015 Q4
Celator Pharma Revenues or Net Sales
--
Cost Of Goods Sold (COGS)--
Celator Pharma Gross Profit
--
Research & Development Expense2.68M2.77M
Selling General & Admin Expense2.32M1.83M
Income Before Depreciation Depletion Amortization-5.01M-4.57M
Depreciation Depletion Amortization--
Non Operating Income-0.01M-
Interest Expense--
Celator Pharma Pretax Income
-5.53M-5.09M
Provision for Income Taxes--0.68M
MinorityInterest--
Investment Gains Losses--
Other Income--
Income Before Extraordinaries & Disc Operations-5.53M-4.41M
Extraordinary Items & Discontinued Operations--
Celator Pharma Profit/ Loss (Net Income)
-5.53M-4.41M
Average Shares used to compute Diluted EPS35.4M34.52M
Average Shares used to compute Basic EPS35.4M34.52M
Income Before Nonrecurring Items-5.53M-4.41M
Income from Nonrecurring Items--
Celator Pharma Earnings Per Share Basic Net
-0.16-0.13
Celator Pharma Earnings Per Share Diluted Net
-0.16-0.13
EPS Diluted Before Nonrecurring Items-0.16-0.13
Preferred Dividends Acc Pd--
Dividends Common--
Dividend Per Share Common0.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.

Celator Pharma stock analysis involves checking at least a few of the important things like:

  • Topline: A growing topline, as seen from the Celator Pharma revenue chart, as isn't the case with Celator Pharma indicates a sagging business. One needs to compare the QoQ topline or sales growth of CPXX stock with its peers like MNK stock and RLYP stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-5.53M for Celator Pharma for 2016 Q1. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called statement of revenue and expense. The CPXX financials along with Celator Pharma historical stock prices provide a lot of details about the firm.

Other Income Statements - Celator Pharmaceuticals Inc Industry Peers

CTI BioPharma income statement, Mallinckrodt income statement, Relypsa income statement